Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national
8
×
national blog main
biotech
national top stories
clinical trials
europe blog main
new york blog main
boston blog main
fda
san francisco blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
indiana blog main
indiana top stories
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
venture capital
wisconsin blog main
wisconsin top stories
abbvie
allergan
alnylam pharmaceuticals
amgen
biogen
brexit
What
medicines
8
×
fda
new
plans
bio
brexit
charting
choppy
class
course
covid
dynamic
end
ipo
migraine
nod
period
post
regulation
regulatory
reveals
roundup
transition
treat
uk
abcellera
abcellera’s
acquisitions
activity
adults
allergan
amgen
announced
antibodies
antibody
approval
approvals
approved
aren’t
based
Language
unset
Current search:
national
×
medicines
×
@xconomy.com
3 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
AbCellera’s Coronavirus “Neutralizing” Antibody Leads Enter Screening
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
5 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines